Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

A. Hurvitz, Sara; Hegg, Roberto; Chung, Wei‐Pang; Im, Seock‐Ah; Jacot, William; Ganju, Vinod; Wing Yan Chiu, Joanne; Xu, Binghe; Hamilton, Erika; Madhusudan, Srinivasan; Iwata, Hiroji; Altıntaş, Sevilay; Henning, Jan‐Willem; Curigliano, Giuseppe; Manuel Pérez-García, José; Kim, Sung‐Bae; Petry, Vanessa; Huang, Chiun‐Sheng; Li, Wěi; Frenel, Jean‐Sébastien; Antolín, Silvia; Yeo, Winnie; Bianchini, Giampaolo; Loi, Sherene; Tsurutani, Junji; Egorov, Anton; Liu, Yali; Cathcart, Jillian; Ashfaque, Shahid; Cortés, Javier

doi:10.1016/s0140-6736(22)02420-5

Public

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Published in The Lancet • Dec 7, 2022

Authors:

Sara A. Hurvitz

Roberto Hegg

Wei‐Pang Chung

Abstract

BACKGROUND: An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast03 trial. The aim of DESTINY-Breast03 was to compa...

Subject

Trastuzumab

Trastuzumab emtansine

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!